Collegium Pharmaceutical, Inc. $COLL Shares Bought by Healthcare of Ontario Pension Plan Trust Fund

Healthcare of Ontario Pension Plan Trust Fund raised its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 49.9% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 61,742 shares of the specialty pharmaceutical company’s stock after buying an additional 20,540 shares during the quarter. Healthcare of Ontario Pension Plan Trust Fund’s holdings in Collegium Pharmaceutical were worth $2,042,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Vanguard Group Inc. boosted its position in Collegium Pharmaceutical by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 2,256,254 shares of the specialty pharmaceutical company’s stock worth $104,465,000 after acquiring an additional 29,876 shares during the last quarter. Massachusetts Financial Services Co. MA raised its holdings in Collegium Pharmaceutical by 65.3% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 1,312,655 shares of the specialty pharmaceutical company’s stock valued at $60,776,000 after acquiring an additional 518,721 shares during the last quarter. Louisiana State Employees Retirement System purchased a new position in Collegium Pharmaceutical in the 1st quarter worth approximately $463,000. Intech Investment Management LLC boosted its holdings in shares of Collegium Pharmaceutical by 25.5% during the 4th quarter. Intech Investment Management LLC now owns 108,855 shares of the specialty pharmaceutical company’s stock worth $5,040,000 after purchasing an additional 22,146 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd acquired a new position in shares of Collegium Pharmaceutical during the 1st quarter worth approximately $686,000.

Analyst Ratings Changes

Several equities research analysts recently commented on COLL shares. Wall Street Zen cut Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Saturday, July 25th. Zacks Research cut Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Tuesday. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Collegium Pharmaceutical in a research note on Monday, July 6th. Finally, Truist Financial upgraded Collegium Pharmaceutical to a “strong-buy” rating in a report on Monday, June 15th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Collegium Pharmaceutical has a consensus rating of “Moderate Buy” and an average price target of $57.50.

Collegium Pharmaceutical Price Performance

COLL stock opened at $35.39 on Friday. Collegium Pharmaceutical, Inc. has a 52-week low of $29.19 and a 52-week high of $50.79. The company has a quick ratio of 1.62, a current ratio of 1.71 and a debt-to-equity ratio of 2.47. The stock has a market cap of $1.15 billion, a price-to-earnings ratio of 17.35 and a beta of 0.73. The business has a fifty day moving average of $34.84 and a two-hundred day moving average of $37.55.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 earnings per share for the quarter, topping analysts’ consensus estimates of $1.52 by $0.24. The business had revenue of $193.52 million during the quarter, compared to analysts’ expectations of $184.47 million. Collegium Pharmaceutical had a return on equity of 95.18% and a net margin of 9.41%.The company’s revenue was up 8.9% compared to the same quarter last year. During the same period in the prior year, the business posted $1.49 EPS. As a group, research analysts anticipate that Collegium Pharmaceutical, Inc. will post 6.76 earnings per share for the current year.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.